STLN Drops −46% in Snapshot Despite Growth as Guidance Narrows
Starling Oncology sold off after its quarterly update. Examine the mixed guidance changes and why stronger revenue does not settle the stock's valuation.
Read the story
AIRS Drops −60% in Snapshot After AirSculpt Cuts Its Annual Outlook
AirSculpt lowered its annual outlook after weaker procedure demand. Explore the earnings catalyst, refinancing and risks behind the AIRS selloff.